BIOLOGICS USE IN CROHN'S DISEASE IN FRANCE

被引：0
|
作者：
Gaudry, J. [1 ]
Morand, F. [2 ]
Willemin, L. [3 ]
Lee, X. Y. [4 ]
Lelli, F. [5 ]
机构：
[1] IMS Hlth, Boulogne, France
[2] IMS Hlth, Paris, France
[3] Janssen Cilag, Issy Les Moulineaux, France
[4] Janssen Cilag AS, Birkerod, Denmark
[5] Janssen Cilag SpA, Cologno Monzese, MI, Italy
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 07期
关键词：
D O I：
10.1016/j.jval.2016.09.976
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PGI32
引用
收藏
页码：A515 / A515
页数：1
相关论文
共 50 条
  • [41] Translational research and efficacy of biologics in Crohn's disease: a cautionary tale
    Auer, Keil
    Trachter, Robert
    Van den Bogaerde, Johan
    Bassaganya-Riera, Josep
    Sorrentino, Dario
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2014, 10 (02) : 219 - 229
  • [42] Biologics Delay Progression of Crohn's Disease, but Not Early Surgery, in Children
    Kerur, Basavaraj
    Machan, Jason T.
    Shapiro, Jason M.
    Cerezo, Carolina S.
    Markowitz, James
    Mack, David R.
    Griffiths, Anne M.
    Otley, Anthony R.
    Pfefferkorn, Marian D.
    Rosh, Joel R.
    Keljo, David J.
    Boyle, Brendan
    Oliva-Hemker, Maria
    Kay, Marsha H.
    Saeed, Shehzad A.
    Grossman, Andrew B.
    Sudel, Boris
    Kappelman, Michael D.
    Schaefer, Marc
    Tomer, Gitit
    Bousvaros, Athos
    Lerer, Trudy
    Hyams, Jeffrey S.
    LeLeiko, Neal S.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2018, 16 (09) : 1467 - 1473
  • [43] Biologics in oral medicine: oral Crohn's disease and orofacial granulomatosis
    O'Neill, I. D.
    Scully, C.
    ORAL DISEASES, 2012, 18 (07) : 633 - 638
  • [44] Commentary: predicting relapse in Crohn's disease patients in remission with biologics
    Andrews, J. M.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2013, 37 (04) : 497 - 498
  • [45] Which biologics best prevent penetrating complications in Crohn's disease?
    Kahi, Charles J.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2024, 22 (02) : 207 - 208
  • [46] Combined Approach with Biologics and Surgery for Enterocutaneous Fistulas In Crohn's Disease
    Fries, Walter
    La Malfa, Giuseppe
    Costantino, Giuseppe
    Repici, Alessandro
    Mazziotti, Silvio
    Navarra, Giuseppe
    INFLAMMATORY BOWEL DISEASES, 2011, 17 (02) : 671 - 673
  • [47] COMPARATIVE EFFECTIVENESS OF BIOLOGICS IN PREVENTING PENETRATING COMPLICATIONS IN CROHN'S DISEASE
    Mccurdy, Jeffrey
    Stwalley, Dustin
    Olsen, Margaret A.
    Deepak, Parakkal
    GASTROENTEROLOGY, 2023, 164 (06) : S648 - S649
  • [48] New biologics in the management of Crohn's disease: focus on certolizumab pegol
    Colombo, Elisabetta
    Bossa, Fabrizio
    Latiano, Anna
    Palmieri, Orazio
    Andriulli, Angelo
    Annese, Vito
    CLINICAL AND EXPERIMENTAL GASTROENTEROLOGY, 2009, 2 : 61 - 68
  • [49] The Role of Immunomodulators and Biologics in the Medical Management of Stricturing Crohn's Disease
    Rodriguez-Lago, Iago
    Gisbert, Javier P.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 (04): : 557 - 566
  • [50] Low muscle mass is associated with efficacy of biologics in Crohn's disease
    Fang, Ye
    Fang, Luyan
    Ye, Mengqian
    Jiang, Hanyue
    Long, Xinyu
    Zhang, Haoxuan
    Zhang, Qianqian
    Lin, Daopo
    Shao, Xiaoxiao
    CLINICAL NUTRITION, 2024, 43 (10) : 2354 - 2363
12345